■論説
がん治療と緩和ケア（3）―がん患者の食欲不振におけるオランザピンの効果
中村 博子, 伊勢 雄也, 片山 志郎
日本医科大学付属病院薬剤部
Treatment of Cancer and Palliative Care (3)Treatment of Cancer-related Anorexia with Olanzapine
Hiroko Nakamura, Yuya Ise and Shirou Katayama
Department of Pharmaceutical Service, Nippon Medical School
Patients with cancer-related anorexia (CRA) have a lack of appetite, early satiety, taste changes, poor performance status, and diminished quality of life. Megestrol acetate is a standard treatment for CRA. Recently, olanzapine has been reported to be effective for treating refractory nausea and vomiting induced by chemotherapy in patients with cancer. A clinical trial has found that the combination of megestrol acetate and olanzapine is effective for patients with CRA. In this article we describe the treatment of CRA using olanzapine.
日医大医会誌 2012; 8(3), 195-198
Key words
cancer-related anorexia, weight loss, olanzapine
Correspondence to
Hiroko Nakamura, Department of Pharmaceutical Service, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
E-mail：nakamu@nms.ac.jp
受付：2012年1月30日 受理：2012年3月28日 |
全文PDF